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Cardiovascular events are the major 
cause of morbidity and mortality among 
chronic kidney disease (CKD) patients. 
A burden of cardiovascular risk factors 
play a role to adverse outcome in 
this population, including traditional 
cardiovascular risk factors as well as 
several CKD-related factors. It is known 
that CKD-related mineral bone disorder 
(BMD) such as hyperphosphatemia, 
calcium overload, vitamin D deficiency, 
excess of vitamin D analogues, secondary 
hyperparathyroidism (SHPT), and 
low PTH levels might contribute for 
cardiovascular disease (CVD).
In the article published in this issue of 
the Brazilian Journal of Nephrology, title 
“Factors associated with subendocardial 
ischemia risk in patients on hemodialysis”, 
Silva et al. evaluated the association between 
subendocardial viability ratio (SEVR) 
and BMD markers in a cohort of patients 
on hemodialysis. The authors reported 
that a more prolonged time spent under 
severe SHPT is related to higher risk of 
subendocardial ischemia, which might not 
be reversed by parathyroidectomy (PTX). 
In addition, they observed that lower SERV 
was associated with female sex and patients 
with lower levels of 25 Vitamin-D.
Although this study has limitation 
by cross-sectional observational design 
and small sample size, it adds relevant 
information regarding non-invasive 
vascular functional assessment for 
vascular dysfunction and long-term 
impact of SHPT on cardiovascular system.
Cardiovascular assessment using non-
invasive structural and functional imaging 
techniques has increased our understanding 
of the cardiovascular complications 
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associated with CKD, including vascular 
and cardiac valvular calcification, 
cardiomyopathy, and arterial stiffness. 
A number of techniques are currently 
available such as cardiac computer 
tomography, single-plane radiography, 
Doppler ultrasound, echocardiography, 
myocardial perfusion scintigraphy, 
applanation tonometry, and magnetic 
resonance imaging.1 Pulse wave analysis 
(PWA) using applanation tonometry 
has emerged as a technique for assessing 
vascular function and has been applied as 
an important research tool in CKD. PWA 
provides several vascular indices such as 
pulse wave velocity (PWV), augmentation 
index, ejection duration index, and SERV. 
PWV has been largely used in patients with 
CKD and mostly reflects arterial stiffness. 
Arterial stiffness causes an increase in 
afterload on the left ventricle resulting in 
left ventricular hypertrophy and reduced 
coronary perfusion. Several studies have 
demonstrated an association between 
vascular calcification and increased arterial 
stiffness in patients with CKD.2 Furthermore, 
PWV enables risk stratification for all-cause 
and cardiovascular mortality on CKD. 
However, PWA measurement has limitation 
mainly because is operator dependent.
In the study from Silva et al., SERV, 
also known as Buckberg index, was 
determined to assess the impact of BMD 
markers on hemodialysis patients. SERV 
is an index of myocardial oxygen supply 
and demand calculated through PWA. 
Contrary to PWV, SERV has been barely 
used in CKD, however this index appears 
to be an interesting surrogate marker for 
CVD and deserve further investigation. 
Recently Ekart et al.3 evaluated a cohort DOI: 10.5935/0101-2800.20160041
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of 90 non-dialysis CKD patients and 39 healthy 
controls and demonstrated that patients with stage 4-5 
CKD and albuminuria more than 1000mg/g showed 
significantly lower SEVR. Furthermore, in a post hoc 
analysis, 212 asymptomatic outpatients with stage 
3-4 CKD followed by 6 months. SEVR correlated 
inversely with vascular calcifications and myocardial 
mass. In addition, reduction of SEVR values during 
follow-up was associated with cardiovascular 
mortality.4 In the study by Silva et al., new advances 
were added since lower SERV was associated with 
suboptimal vitamin D levels and severe SHPT. Al 
Mheid et al.5 reported an association of vitamin D 
insufficiency and lower SERV in 554 healthy adults. 
Normalization of vitamin D status at 6 months was 
associated with increases in SERV. However, impact 
of PTH on vascular dysfunction assessed by SERV in 
CKD patients had not yet been demonstrated.
Secondary hyperparathyroidism is associated with 
an increased risk of cardiovascular morbidity and 
mortality. Cardiovascular effect of PTH is recognized 
but complex due to coexistence of many confounding 
factors able to impair vascular function in CKD 
patients. Although the mechanisms underlying leading 
to CVD are not clearly understood, there are evidence 
that the cardiovascular system can be target for 
PTH. Actually, mRNA expression of PTH receptors 
have been demonstrated on vascular endothelial and 
smooth muscle cells. In addition, PTH is thought to 
have direct and indirect effects on cardiomyocytes, 
vascular smooth muscle cells of myocardial arterioles, 
and even fibroblasts that might contribute for cardiac 
hyperthrophy, and fibrosis.6
Furthermore, Neves et al.7 demonstrated that 
administration of PTH induced aortic calcification in 
the presence of normal calcium and phosphorus serum 
levels in a model of parathyroidectomized chronic 
kidney disease rat, suggesting that PTH may also have 
a contributory role in vascular calcification. Therefore, 
it is plausible that high PTH levels for long- term might 
contribute in the pathophysiology of CVD such as 
atherosclerosis, arterial stiffness, vascular calcification, 
and cardiomyopathy in CKD patients. However, the 
reverse of vascular dysfunction with SHPT treatment 
by reducing PTH levels is a matter of discussion. In a 
clinical study from Osto et al.,8 coronary microvascular 
dysfunction was completely restored in patients with 
primary HPT who underwent to PTX.
Unlike, Silva et al. observed that the time spent on 
SHPT was independent associated with lower SERV and 
it was no reverted after PTX. Permanent cardiovascular 
damage might be a plausible reason due to long-time 
of severe SHPT. Additionally, patients of the study had 
a long-time on dialysis treatment and under several 
cardiovascular risk factors other than those related to 
BMD. Despite of fact that microvascular dysfunction 
was no reverted after PTX, recent systematic review and 
meta-analysis demonstrated that PTX was associated 
with decreased risks of all-cause and cardiovascular 
mortalities compared to medical treatments in CKD 
patients with SHPT.9
In conclusion, paper from Silva et al. is really 
welcome. It is important to highlight that our 
understanding of the cardiovascular manifestations 
of SHPT remains still incomplete. Can cardiovascular 
damage and subendocardial ischemia be prevented or 
treated in patients with CKD and SHPT? This and many 
other questions need to be addressed in further studies. 
Furthermore, we need to keep in mind that effort should 
be done to find better control of BMD early on CKD 
avoiding future adverse consequences including severe 
SHPT. In this same way, PTX should not be delayed to 
avoid permanent damage on cardiovascular system due 
to long-time under severe SHPT.
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